Drug Monograph

Drug/Drug Class:	**Invega Trinza™ (paliperidone palmitate) extended-release injection / Atypical Antipsychotics**
Prepared for:	MO HealthNet
Prepared by:	Xerox Heritage, LLC

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Invega Trinza™ is available as an extended-release injectable suspension for intramuscular injection in dose strengths of 273 mg, 410 mg, 546 mg, and 819 mg paliperidone palmitate.
Manufacturer:	Janssen Pharmaceuticals, Inc., Titusville, NJ 08560
Indications:	Invega Trinza™ is indicated for the treatment of schizophrenia in patients after they have been adequately treated with Invega Sustenna™ for at least four months.
Costs:	$2,319.53 per syringe of 273 mg, $2,315.11 per syringe of 410 mg, $2,319.60 per syringe of 546 mg, and $2319.56 per syringe of 819 mg of Invega Trinza™. Maximum Allowable Cost
Summary of Findings:	The Division recommends adding this drug to the current atypical antipsychotic clinical edit.
Status Recommendation:	☐ Prior Authorization (PA) Required ☐ Open Access ☐ Fiscal Edit ☒ Clinical Edit
Type of PA Criteria:	☐ Increased Risk of ADE ☐ Non-Preferred Agent ☒ Appropriate Indications ☐ No PA Required

Prepared By: Luke Boehmer, Pharm. D.
Date: August 31, 2015